Literature DB >> 25762793

Reply to "adequate design of pharmacokinetic-pharmacodynamic studies will help optimize tuberculosis treatment for the future".

Ana Requena-Méndez1, Geraint Davies2, David A J Moore3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25762793      PMCID： PMC4356803          DOI： 10.1128/AAC.05182-14

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  6 in total

1.  Pharmacokinetics of isoniazid under fasting conditions, with food, and with antacids.

Authors:  C A Peloquin; R Namdar; A A Dodge; D E Nix
Journal:  Int J Tuberc Lung Dis       Date:  1999-08       Impact factor: 2.373

2.  Adequate design of pharmacokinetic-pharmacodynamic studies will help optimize tuberculosis treatment for the future.

Authors:  Marieke G G Sturkenboom; Onno W Akkerman; Mathieu S Bolhuis; Wiel C M de Lange; Tjip S van der Werf; Jan-Willem C Alffenaar
Journal:  Antimicrob Agents Chemother       Date:  2015-04       Impact factor: 5.191

3.  Comment on: Clinical significance of 2 h plasma concentrations of first-line anti-tuberculosis drugs: a prospective observational study.

Authors:  Jotam G Pasipanodya; Shashikant Srivastava; Tawanda Gumbo
Journal:  J Antimicrob Chemother       Date:  2014-09-01       Impact factor: 5.790

Review 4.  Therapeutic drug monitoring in the treatment of tuberculosis.

Authors:  Charles A Peloquin
Journal:  Drugs       Date:  2002       Impact factor: 9.546

5.  Population pharmacokinetic modeling of isoniazid, rifampin, and pyrazinamide.

Authors:  C A Peloquin; G S Jaresko; C L Yong; A C Keung; A E Bulpitt; R W Jelliffe
Journal:  Antimicrob Agents Chemother       Date:  1997-12       Impact factor: 5.191

6.  Effects of dosage, comorbidities, and food on isoniazid pharmacokinetics in Peruvian tuberculosis patients.

Authors:  Ana Requena-Méndez; Geraint Davies; David Waterhouse; Alison Ardrey; Oswaldo Jave; Sonia Llanet López-Romero; Stephen A Ward; David A J Moore
Journal:  Antimicrob Agents Chemother       Date:  2014-09-15       Impact factor: 5.191
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.